January 30, 2017
Cambridge, USA

Steps Forward For Duchenne Muscular Dystrophy

As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.

We set out to fulfill the need for a company focused solely on solving Duchenne muscular dystrophy (DMD) for every patient, regardless of their genetic mutation or stage of disease. I believe that we have been true to this goal, and will continue to be, because of our promise to the community: to advance only the best science, do things the right way, act with a sense of passion and urgency, and listen to and partner with those who are experiencing the disease firsthand.

2016 was an important year for Solid. We grew our team from six to more than 30 people, achieved important regulatory milestones and opened an office in London. We also generated, and are continuing to generate, a ton of preclinical data to ensure that we know all there is to know about our lead gene therapy compound, SGT-001. It’s what our patients deserve.

Understanding the manufacturing challenges inherent to this program, we also invested heavily in process development and built capabilities that will allow us, upon success in clinical trials, to scale up production and make our treatment widely available to patients.

With this strong foundation in place, our priorities for 2017 are to move SGT-001 into the clinic, grow our pipeline and further build our company with more great talent and resources. 

In the second half of the year, we plan to initiate our first clinical study to evaluate the safety and efficacy of SGT-001, a therapy that we believe has the potential to benefit most DMD patients, irrespective of genetic mutations.

We are also working to build our pipeline of therapies that address a range of symptoms associated with DMD. We added two programs to this pipeline in 2016, and walked away from others that didn’t meet our requirements and expectations. Our goal is to generate strong preclinical data for these candidates and move forward only those that impress us most.

I am especially proud of our team at Solid and feel the commitment and passion across our growing company. However, we would not be where we are today without our partnerships with the DMD community. Together, we are working hard to advance the science and are taking important steps forward to solve this terrible disease.

I will keep you updated on our progress.


Ilan Ganot, CEO of Solid Biosciences

Related news


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.


Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.


Solid Biosciences Community Update Q2 2016


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


More information about Solid?

Please subscribe to receive our latest news